Шизофрения. Краткое введение

The genetic «spectrum» of schizophrenia: K. S. Kendler et al., «The structure of schizotypy — a pilot multitrait twin study». Psychiatry Research (1991) 36:19–36.

Глава 3

The central executive: A. Baddeley, Working Memory (Oxford University Press, 1986).

IQ in schizophrenia: C. D. Frith, J. Leary, C. Cahill and E. C. Johnstone, «Performance on psychological tests. Demographic and clinical correlates of the results of these tests», British Journal of Psychiatry (1991), suppl. 13: 26-9, 44-6.

IQ. decline in schizophrenia: J. Rabinowitz et al., «Cognitive and behavioural functioning in men with schizophrenia both before and shortly after first admission to hospital — cross-sectional analysis», British Journal of Psychiatry (2000), 177: 26–32.

IQ and institutionalization: E. C. Johnstone et al., «The dementia of dementia praecox», Acta Psychiatrica Scandinavica (1978), 57: 305-24.

IQ and community care: C. Kelly et al., «Nithsdale Schizophrenia Surveys 20 — cognitive function in a catchment-area-based population of patients with schizophrenia», British Journal of Psychiatry (2000), 177: 348-53.

IQ and drugs: S. Mohamed et al., «Generalized cognitive deficits in schizophrenia — a study of first-episode patients». Archives of General Psychiatry (1999), 56(8): 749-54.

The core cognitive impairment in schizophrenia: B. Elvevag and T. E. Goldberg, «Cognitive impairment in schizophrenia is the core of the disorder». Critical Reviews in Neurobiology (2000), 14(1): 1-21.

Motivation in schizophrenia: S. G. Heilman et al., «Monetary reinforcement and Wisconsin Card Sorting performance in schizophrenia: why show me the money?», Schizophrenia Research (1998), 34(1–2): 67–75.

Single case approach: T. Shallice, P. W. Burgess, and C. D. Frith, «Can the neuropsychological case-study approach be applied to schizophrenia?». Psychological Medicine (1991), 21: 661-73.

Classifying symptoms: T. J. Crow, «Molecular pathology of schizophrenia: more than one disease process?», British Medical Journal (1980), 280(6207): 66-8.

Intellectual functioning and symptoms: E. C. Johnstone and C. D. Frith, «Validation of three dimensions of schizophrenic symptoms in a large unselected sample of patients». Psychological Medicine (1996), 26(4): 669-79.

Genius and madness: N. C. Andreasen, «Creativity and mental illness: prevalence rates in writers and their first-degree relatives». The American Journal of Psychiatry (1987), 144(10): 1.288-92; A. M. Ludwig, «Creative achievement and psychopathology: comparison among professions», American Journal of Psychotherapy (1992), 46(3): 330-56.

Superior abilities in the relatives of patients with schizophrenia: J. L. Karlsson, «Mental abilities of male relatives of psychotic patients», Acta Psychiatrica Scandinavica (2001), 104(6): 466-8.

Глава 4

Amphetamine psychosis: P. H. Connell, Amphetamine Psychosis (Maudsley Monographs, 1958); S. Tatetsu, «Metamphetamine psychosis», in Current Concepts of Amphetamine Abuse, ed. E. H. Elinwood (Rockville NIMH, 1972).

Experimental studies of amphetamine: J. D. Griffith, J. H. Cavanaugh, J. Held, et al., «Experimental psychosis induced by the administration of d-amphetamine», in Amphetamine and Related Compounds, ed. E. Costa and S. Garattini (Raven Press, 1970), pp. 897–904;

В. M. Angrist and S. Gershon, «The phenomenology of experimentally induced amphetamine psychosis: Preliminary observations». Biological Psychiatry (1970), 2: 95-107.

Amphetamine and dopamine: L. Kokkinidis and H. Anisman, «Amphetamine psychosis and schizophrenia — a dual model», Neuroscience and Biobehavioral Reviews (1981), 5 (4): 449-61.

Cannabis and schizophrenia: S. Andreasson, A. Engstrom, P. Allebeck, and U. Rydberg, «Cannabis and schizophrenia — a longitudinal study of Swedish conscripts». Lancet (1987), 2 (8574): 1483-6; W. Hall and L. Degenhardt, «Cannabis use and psychosis: a review of clinical and epidemiological evidence», Australian and New Zealand Journal of Psychiatry (2000), 34 (1): 26–34.

The cannabis receptor: M. Glass, «The role of cannabinoids in neurodegenerative diseases». Progress in Neuro-Psychopharmacology and Biological Psychiatry (2001), 25 (4): 743-65.

PCP and schizophrenia: D. C. Javitt and S. R. Zukin, «Recent advances in the phencyclidine model of schizophrenia», American Journal of Psychiatry (1991), 148 (10): 1301-8.